Kennedy Opposition Halts Device User Fee, Third-Party Expansion Momentum
This article was originally published in The Gray Sheet
Executive SummaryHouse and Senate conferees are likely to include Prescription Drug User Fee Act (PDUFA) reauthorization and medical device reforms in the Public Health Security and Bioterrorism Response Act of 2001 (HR 3448) when they meet to reconcile the measure, as early as the week of April 15
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.